Intravenous thrombolysis in the treatment of acute ischaemic stroke: 3, 4.5, or 6 hours?;Dożlna tromboliza w leczeniu świeżego udaru niedokrwiennego: 3, 4,5 czy 6 godzin?

Neurologia i Neurochirurgia Polska

Volumn 43, Issue 3, 2009, Pages 213-215

  Kwieciński, Hubert ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; PLACEBO; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE DISEASE; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; EDITORIAL; HUMAN; AGED; BRAIN ISCHEMIA; FEMALE; HOSPITALIZATION; MALE; MEDICAL RECORD; NOTE; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; STATISTICS; STROKE;

AGED; BRAIN ISCHEMIA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MEDICAL RECORDS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 68149123586     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (12)

1. Hacke W., Donnan G., Fieschi C. i wsp. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-774.
2. Członkowska A., Kobayashi A., Lewis S. i wsp. The Third International Stroke Trial: Thrombolysis (IST-3) in Poland: are we recruiting the right patients? Neurol Neurochir Pol 2009; 43: 228-235.
3. Hacke W., Kaste M., Bluhmki E. i wsp. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
4. Summerskill W. Paper of the year 2008: results. Lancet 2009; 373: 283-284.
5. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457-507 (tłumaczenie na jezyk polski: Med Prakt, wyd. specjalne 1/2009, str. 1-64).
6. Del Zoppo G.J., Saver J.L., Jauch E.C. i wsp. Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen Activator. A Science Advisory From the American Heart Association/American Stroke Association. 2009 May 28. [Epub ahead of print].
7. Wahlgren N., Ahmed N., Davalos A. i wsp. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 275-282.
8. Wahlgren N., Ahmed N., Dávalos A. i wsp. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008; 372: 1303-1309.
9. Schellinger P. EPITHET: failed chance or new hope? Lancet Neurol 2008; 7: 286-287.
10. Davis S.M., Donnan G.A., Parsons M.W. i wsp. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008; 7: 299-309.
11. Albers G.W., Thijs V.N., Wechsler L. i wsp. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006; 60: 508-517.
12. Sandercock P., Wardlaw J., Dennis M. i wsp. EPITHET - where next? Lancet Neurol 2008; 7: 570-571.